Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SalubrisBio Reports $35 Million Infusion from Parent for Novel Biologic Drugs

publication date: Mar 28, 2023

Salubris Biotherapeutics has received $35 million from its parent, Shenzhen Salubris Pharma, to advance its lead candidate, a treatment for heart failure with preserved ejection fraction (HFpEF), currently in a US Phase Ib trial. JK07 is a recombinant fusion protein that combines a fully human immunoglobulin IgG1 mAb and an active polypeptide fragment of the human growth factor neuregulin (NRG-1). The capital will support Phase Ib and II trials of JK07. Salubris Bio, a Gaithersburg, Maryland pharma, was founded in 2016 to develop novel complex biologic drugs for cardiovascular, oncology and neurodegenerative diseases. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital